» Articles » PMID: 26379935

Pyrosequencing Analysis for Mutations in EmbB Codon306 Among Clinical Mycobacterium Tuberculosis Isolates from Qingdao, China

Overview
Specialty General Medicine
Date 2015 Sep 18
PMID 26379935
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, our objectives was to analyze the molecular characteristics of mutation at embB codon306 in Mycobacterium tuberculosis in Qingdao by pyrosequencing technology, and to assess the value of embB codon306 used as a molecular marker to diagnose multidrug resistant (MDR) TB strains. Pyrosequencing was used to detect mutations at embB codon306 among M. tuberculosis isolates from tuberculosis (TB) patients in Qingdao. The correlation between embB306 mutation and MDR phenotype was evaluated by comparing with conventional drug susceptibility testing results. 60.9% of MDR strains and 15.2% of non-MDR strains carried embB306 mutation, respectively. The percentage of MDR-TB harboring embB306 mutation was significantly higher than that of non- MDR-TB (χ(2)=15.09, P < 0.01). EmbB306 mutation serving as a marker to diagnose MDR-TB comparing with the traditional susceptibility test, the specificity, sensitivity and accuracy were 85%, 61%, and 77%, respectively. EmbB306 mutation is the main mechanism of TB resistance to multidrug in Qingdao, showing an association with the MDR. Pyrosequencing should be a good diagnostic tool for MDR-TB in Qingdao.

Citing Articles

Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis.

Schwab T, Perrig L, Goller P, Guebely De la Hoz F, Lahousse A, Minder B Lancet Infect Dis. 2024; 24(10):1162-1176.

PMID: 38795712 PMC: 11881551. DOI: 10.1016/S1473-3099(24)00263-9.

References
1.
Sreevatsan S, Stockbauer K, Pan X, Kreiswirth B, Moghazeh S, Jacobs Jr W . Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother. 1997; 41(8):1677-81. PMC: 163984. DOI: 10.1128/AAC.41.8.1677. View

2.
Ahmad S, Jaber A, Mokaddas E . Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinb). 2007; 87(2):123-9. DOI: 10.1016/j.tube.2006.05.004. View

3.
Hazbon M, Bobadilla Del Valle M, Guerrero M, Varma-Basil M, Filliol I, Cavatore M . Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother. 2005; 49(9):3794-802. PMC: 1195424. DOI: 10.1128/AAC.49.9.3794-3802.2005. View

4.
Zhao Y, Xu S, Wang L, Chin D, Wang S, Jiang G . National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366(23):2161-70. DOI: 10.1056/NEJMoa1108789. View

5.
Parsons L, Salfinger M, Clobridge A, Dormandy J, Mirabello L, Polletta V . Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother. 2005; 49(6):2218-25. PMC: 1140517. DOI: 10.1128/AAC.49.6.2218-2225.2005. View